<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01637259</url>
  </required_header>
  <id_info>
    <org_study_id>MARCH-Kirby renal</org_study_id>
    <nct_id>NCT01637259</nct_id>
  </id_info>
  <brief_title>MARCH Renal Substudy</brief_title>
  <acronym>MARCHrenal</acronym>
  <official_title>Maraviroc Switch Collaborative Study Renal Substudy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney disease (CKD) is an emerging problem in patients with treated HIV.
      Antiretroviral therapy associated renal dysfunction has been predominantly described in terms
      of reduced glomerular filtration (eGFR). Proteinuria is a key component of CKD and may occur
      in the absence of significant reductions in eGFR. This substudy is an exploration of changes
      in urinary protein excretion in a randomised, open-label study to evaluate the efficacy and
      safety of MVC as a switch for either nucleoside or nucleotide analogue reverse transcriptase
      inhibitors (N(t)RTI) or boosted protease inhibitors (PI/r) in HIV-1 infected individuals with
      stable, well-controlled plasma HIV-RNA while taking their first N(t)RTI + PI/r regimen of
      combination antiretroviral therapy (cART).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this substudy of MARCH is to characterize the changes in protein and salt
      excretion through the kidney utilising the randomised arms of the parent study MARCH. The
      investigators hypothesize there will be an improvement in proteinuria in those switching to
      maraviroc containing regimens.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in proteinuria and albuminuria between baseline and week 96</measure>
    <time_frame>96 weeks</time_frame>
    <description>To compare the change in protein and albumin excretion as measured by the urine PCR and ACR through the kidneys between the randomised and standard of care (control) arm of MARCH.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in renal tubular function between baseline and week 96</measure>
    <time_frame>96 weeks</time_frame>
    <description>To evaluate the following aspects of renal function at baseline and changes within and between study groups:
Tubular function defined as proximal tubular function; ascending thick loop of Henle; distal tubular function; volume and renal potassium handling;
Non-tubular function i.e. eGFR; Urine albumin:creatinine ratio;
Determine factors associated with renal dysfunction within the cohort e.g. demographics, HIV related, HIV-treatment related, co-morbidities, concomitant medication (such as ACE inhibitors and ARB; PI/r co-administered with TDF); TDF use;</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Proteinuria</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>NRTI + PI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>arm 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PI + maraviroc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>arm 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRTI + maraviroc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>arm 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors</intervention_name>
    <description>NRTI + PI</description>
    <arm_group_label>NRTI + PI</arm_group_label>
    <other_name>tenofovir</other_name>
    <other_name>emtricitabine</other_name>
    <other_name>zidovudine</other_name>
    <other_name>abacavir</other_name>
    <other_name>lamivudine</other_name>
    <other_name>atazanavir</other_name>
    <other_name>lopinavir</other_name>
    <other_name>darunavir</other_name>
    <other_name>fosamprenavir</other_name>
    <other_name>ritonavir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm 2 boosted protease inhibitors and maraviroc</intervention_name>
    <description>PI + maraviroc</description>
    <arm_group_label>PI + maraviroc</arm_group_label>
    <other_name>maraviroc</other_name>
    <other_name>atazanavir</other_name>
    <other_name>lopinavir</other_name>
    <other_name>darunavir</other_name>
    <other_name>fosamprenavir</other_name>
    <other_name>ritonavir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc</intervention_name>
    <description>NRTI + maraviroc</description>
    <arm_group_label>NRTI + maraviroc</arm_group_label>
    <other_name>maraviroc</other_name>
    <other_name>tenofovir</other_name>
    <other_name>emtricitabine</other_name>
    <other_name>zidovudine</other_name>
    <other_name>abacavir</other_name>
    <other_name>lamivudine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written, informed consent for participation in the substudy

          -  Enrolled into the substudy either at or before the week 0 visit of the main study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waldo Belloso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Italiano de Buenos Aires</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Kelly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brisbane Sexual Health and HIV Service</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad de Buenos Aires</state>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos J M Ramos Mejia</name>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad de Buenos Aires</state>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación IDEAA</name>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad de Buenos Aires</state>
        <zip>C1405CKC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brisbane Sexual Health and HIV Service</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Alberta Clinic</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2R OX7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network - Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Opus/Lori</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitat Zu Koln</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie, Hepatologie und Infektiologie, MX-Ambulanz</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya Medical Center</name>
      <address>
        <city>Nagoya</city>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutriciòn Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <state>Tlalpan DF</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn University Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Lothian</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton &amp; Sussex University NHS Trust</name>
      <address>
        <city>Brighton</city>
        <state>Sussex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Chile</country>
    <country>France</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <last_update_submitted>January 18, 2016</last_update_submitted>
  <last_update_submitted_qc>January 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>proteinuria</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Fosamprenavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

